Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Stanozolol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR known ✓ | P10275 | 2/20 | 0.59 |
| ▸ | SHBG | P04278 | 5/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.59 |
| ▸ | PGR | P06401 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.59 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.59 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.59 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.59 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.59 |
| ▸ | MGAM | O43451 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.49 |
| ▸ | ESR1 | P03372 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Stanozolol SCHEMBL44099 | 0.86 | CYP2C19 (0.64) | SHBGMAPK1POLBNR3C1PGR | |
| Stanozolol SCHEMBL12417517 | 0.86 | CYP2C19 (0.64) | SHBGMAPK1POLBNR3C1PGR | |
| Stanozolol SCHEMBL19645424 | 0.86 | CYP2C19 (0.64) | SHBGMAPK1POLBNR3C1PGR | |
| Stanozolol SCHEMBL6151066 | 0.86 | CYP2C19 (0.64) | SHBGMAPK1POLBNR3C1PGR | |
| SCHEMBL19625269 | 0.85 | AR (0.52) | SHBGNR3C1PGRCYP3A4HSD17B10 | |
| SCHEMBL10269436 | 0.85 | AR (0.52) | SHBGNR3C1PGRCYP3A4HSD17B10 | |
| SCHEMBL19634237 | 0.85 | AR (0.52) | SHBGNR3C1PGRCYP3A4HSD17B10 | |
| Stanozolol SCHEMBL15609109 | 0.84 | ALDH1A1 (0.56) | SHBGNR3C1PGRCYP3A4HSD17B10 | |
| Oxymetholone SCHEMBL2024270 | 0.80 | ADORA3 (0.74) | SHBGMAPK1POLBNR3C1PGR | |
| Stanozolol SCHEMBL329926 | 0.78 | LMNA (0.63) | SHBGMAPK1POLBNR3C1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103717597-B | Heterocyclic compounds as kinase inhibitors | 原真股份有限公司 | 2017-07-04 | — | — | CN | disclosed |
| CN-103492389-B | Pyrazolo [4,3-d] pyrimidine as inhibitors of kinases | 原真股份有限公司 | 2016-09-14 | — | — | CN | disclosed |
| EP-2699572-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | Origenis GmbH (DE) | 2014-02-26 | — | — | EP | disclosed |
| WO-2012143143-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2012-10-26 | — | — | WO | disclosed |